Leptin: A Novel Therapeutic Strategy for Alzheimer's Disease
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Adipocyte-derived leptin appears to regulate a number of features defining Alzheimer's disease (AD) at the molecular and physiological level. Leptin has been shown to reduce the amount of extracellular amyloid beta, both in cell culture and animal models, as well as to reduce tau phosphorylation in neuronal cells. Importantly, chronic administration of leptin resulted in a significant improvement in the cognitive performance of transgenic animal models. In AD, weight loss often precedes the onset of dementia and the level of circulating leptin is inversely proportional to the severity of cognitive decline. It is speculated that a deficiency in leptin levels or function may contribute to systemic and CNS abnormalities leading to disease progression. Furthermore, a leptin deficiency may aggravate insulin-controlled pathways, known to be aberrant in AD. These observations suggest that a leptin replacement therapy may be beneficial for these patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Central nervous system control of food intake
Schwartz, M. W., Woods, S. C., Porte, D., Seeley, R. J., & Baskin, D. G. (2000) · Nature · doi:10.1038/35007534 · Cited by 6,451 · cited 1×
“insulin sensitivity [2–4], and neuronal activity and protection [5].”
Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210
Identification and expression cloning of a leptin receptor, OB-R.
Tartaglia, L. A., Dembski, M., Weng, X., Deng, N., Culpepper, J., Devos, R., Richards, G. J., Campfield, L. A., Clark, F. T., Deeds, J., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90151-5 · Cited by 3,496
RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease
Yan, S. D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., Slattery, T., Zhao, L., Nagashima, M., Morser, J., et al. (1996) · Nature · doi:10.1038/382685a0 · Cited by 2,012 · cited 1×
“products (RAGE) [46] and scavenger receptors [47];”
Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy
Shimomura, I., Hammer, R. E., Ikemoto, S., Brown, M. S., & Goldstein, J. L. (1999) · Nature · doi:10.1038/43448 · Cited by 1,038 · cited 1×
“insulin sensitivity [2–4], and neuronal activity and protection [5].”
Aph-1, Pen-2, and Nicastrin with Presenilin Generate an Active γ-Secretase Complex
De Strooper, B. (2003) · Neuron · doi:10.1016/s0896-6273(03)00205-8 · Cited by 965 · cited 1×
“multi-protein complex containing PS1 fragments [45].”
Chishti, M. A., Yang, D.-S., Janus, C., Phinney, A. L., Horne, P., Pearson, J., Strome, R., Zuker, N., Loukides, J., French, J., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100710200 · Cited by 955 · cited 1×
“ly onset of plaque deposition in the cortex and hippocampus [92] and develop pathology at a younger age”
Central obesity and increased risk of dementia more than three decades later
Whitmer, R. A., Gustafson, D. R., Barrett-Connor, E., Haan, M. N., Gunderson, E. P., & Yaffe, K. (2008) · Neurology · doi:10.1212/01.wnl.0000306313.89165.ef · Cited by 803
Risner, M. E., Saunders, A. M., Altman, J. F. B., Ormandy, G. C., Craft, S., Foley, I. M., Zvartau-Hind, M. E., Hosford, D. A., Roses, A. D., & for the Rosiglitazone in Alzheimer's Disease Study Group (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500369 · Cited by 686
β-Amyloid fibrils induce tau phosphorylation and loss of microtubule binding
Busciglio, J., Lorenzo, A., Yeh, J., & Yankner, B. A. (1995) · Neuron · doi:10.1016/0896-6273(95)90232-5 · Cited by 595
Cited by
Association of Plasma Leptin Levels With Incident Alzheimer Disease and MRI Measures of Brain Aging
Lieb, W. (2009) · JAMA · doi:10.1001/jama.2009.1836 · Cited by 428
Blüher, M., & Mantzoros, C. S. (2015) · Metabolism · doi:10.1016/j.metabol.2014.10.016 · Cited by 399
Jeon, B. T., Jeong, E. A., Shin, H. J., Lee, Y., Lee, D. H., Kim, H. J., Kang, S. S., Cho, G. J., Choi, W. S., & Roh, G. S. (2012) · Diabetes · doi:10.2337/db11-1498 · Cited by 351
Visceral fat is associated with lower brain volume in healthy middle‐aged adults
Debette, S., Beiser, A., Hoffmann, U., DeCarli, C., O'Donnell, C. J., Massaro, J. M., Au, R., Himali, J. J., Wolf, P. A., Fox, C. S., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22062 · Cited by 253
Chakrabarti, S., Kumar Khemka, V., Banerjee, A., Chatterjee, G., Ganguly, A., & Biswas, A. (2015) · Aging and disease · doi:10.14336/ad.2014.002 · Cited by 134
Metadata
- Authors
- Tezapsidis, N., Johnston, J. M., Smith, M. A., Ashford, J. W., Casadesus, G., Robakis, N. K., Wolozin, B., Perry, G., Zhu, X., Greco, S. J., & Sarkar, S.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2009-04-17
- Volume
- 16
- Issue
- 4
- Pages
- 731-740
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W151131805
- Cited by
- 126
- References
- 19
- FWCI
- 9.05
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Leptin: A Novel Therapeutic Strategy for Alzheimer's Disease. https://app.cochat.ai/papers/10.3233/jad-2009-1021
- The paper
- Tezapsidis, N., Johnston, J. M., Smith, M. A., Ashford, J. W., Casadesus, G., Robakis, N. K., Wolozin, B., Perry, G., Zhu, X., Greco, S. J., & Sarkar, S. (2009). Leptin: A Novel Therapeutic Strategy for Alzheimer's Disease. Journal of Alzheimer's Disease. https://doi.org/10.3233/jad-2009-1021
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.